NCT04081259 2025-05-08LY3214996 in Patients With AML Who Are Not Candidates for Standard TherapyDana-Farber Cancer InstitutePhase 1 Completed17 enrolled
NCT04043845 2020-02-05ERK 1/2 Signaling in Ibrutinib Resistant B-cell MalignanciesDana-Farber Cancer InstitutePhase 1 Withdrawn